FibroGen, Inc. [NASDAQ:FGEN]: Analyst Rating and Earnings
Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to FibroGen, Inc. [FGEN], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of December. On average, stock market experts give FGEN an Buy rating. The average 12-month price forecast for this stock is $71.00, with the high estimate being $85.00, the low estimate being $50.00 and the median estimate amounting to $74.00. This is compared to its latest closing price of $48.03.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for FibroGen, Inc. [FGEN] is sitting at 1.50. This is compared to 1 month ago, when its average rating was 1.83.
For the quarter ending in Sep-18 FibroGen, Inc. [FGEN] generated $0.03 billion in sales. That’s 20.42% lower than the average estimate of $0.04 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Tue 26 Feb (In 46 Days).
Fundamental Analysis of FibroGen, Inc. [FGEN]
Now let’s turn to look at profitability: with a current Operating Margin for FibroGen, Inc. [FGEN] sitting at -97.57, this company’s Net Margin is now -87.80%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -25.18, and its Return on Invested Capital has reached -10.50%. Its Return on Equity is -35.10, and its Return on Assets is -18.45. These metrics suggest that this FibroGen, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, FibroGen, Inc. [FGEN] has generated a Total Debt to Total Equity ratio of 19.37. Similarly, its Total Debt to Total Capital is 16.23, while its Total Debt to Total Assets stands at 12.14. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 19.37, and its Long-Term Debt to Total Capital is 16.23. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is -27.71. The Enterprise Value to Sales for this firm is now 21.90, and its Total Debt to Enterprise Value stands at 0.04. FibroGen, Inc. [FGEN] has a Price to Book Ratio of 6.94.
Shifting the focus to workforce efficiency, FibroGen, Inc. [FGEN] earns $297,087 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 13.30 and its Total Asset Turnover is 0.18. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 9.69 and its Current Ratio is 9.69. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: FibroGen, Inc. [FGEN] has 85.84M shares outstanding, amounting to a total market cap of $4.11B. Its stock price has been found in the range of 37.27 to 68.55. At its current price, it has moved by -30.11% from its 52-week high, and it has moved 28.55% from its 52-week low.
This stock’s Beta value is currently 1.70, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 62.27. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is FibroGen, Inc. [FGEN] a Reliable Buy?
FibroGen, Inc. [FGEN] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.